专利检索 ap:("CAYMAN CHEMICAL COMPANY INCORPORATED") AND inv:"Gregory William Endres" 第 1 页

1.

发明授权
Amine salts of a prostacyclin analog 有权

公开(公告)号：US10155716B2

公开(公告)日：2018-12-18

申请号：US15852922

申请日：2017-12-22

申请人： CAYMAN CHEMICAL COMPANY INCORPORATED

发明人： Gilles Chambournier , Gregory William Endres , Kirk William Hering , Victor Fedij , Hussein Mahmoud Mahmoud

IPC分类号： C07C29/09 , C07C59/72 , C07F7/18 , C07C41/26 , C07C51/09 , C07C51/347 , C07C51/41 , C07C45/29 , C07C51/00

摘要： The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.

2.

发明申请
FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS 审中-公开
标题翻译：用于测试化合物的测定化合物的荧光分子探针与SAM利用蛋白质的竞争性结合

公开(公告)号：US20150322107A1

公开(公告)日：2015-11-12

申请号：US14801897

申请日：2015-07-17

申请人： Cayman Chemical Company, Incorporated , The Regents of the University of Michigan

发明人： Stephen Douglas Barrett , Daniel Austin Bochar , Levi Lynn Blazer , Fred Lawrence Ciske , Gregory William Endres , Jeffrey Keith Johnson , Gregory Scott Keyes , Ranjinder Singh Sidhu , Raymond C. Trievel , Margaret Lynn Collins

IPC分类号： C07H19/16 , G01N33/58

CPC分类号： G01N33/582 , C07D471/04 , C07D473/34 , C07D519/00 , C07H19/16 , G01N21/6428 , G01N2201/061 , G01N2333/91011

摘要： Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding.

摘要翻译： 测定方法通常可以包括形成均匀的测定混合物，其包含目标SAM利用蛋白质，荧光检测分析物和测试化合物，孵育和测量发射的FP或TR-FRET信号，以确定测试化合物-SM利用蛋白质结合的量度。测定混合物包含SAM-利用蛋白质和在不存在测试化合物的情况下与SAM利用蛋白质结合的荧光检测分析物。测定混合物可进一步包含测试化合物。测定混合物实施方案可以产生FP或TR-FRET信号特性，其是测试化合物和检测分析物与SAM-利用蛋白的固有结合相互作用的函数。荧光检测分析物包含荧光团部分，共价连接体部分和SAM-利用蛋白质配体部分，并且可用于FP或TR-FRET测定以测量测试化合物结合。

3.

发明授权
Methods of synthesizing a prostacyclin analog 有权

公开(公告)号：US09908834B2

公开(公告)日：2018-03-06

申请号：US15583457

申请日：2017-05-01

申请人： CAYMAN CHEMICAL COMPANY INCORPORATED

发明人： Kirk William Hering , Gilles Chambournier , Gregory William Endres , Victor Fedij , Thomas James Krell, II , Hussein Mahmoud Mahmoud

IPC分类号： C07C41/26 , C07D303/16 , C07C51/347 , C07D301/00 , C07C45/29 , C07C41/44 , C07D301/32 , C07C205/57 , C07F7/18 , C07D317/22 , C07D303/14 , C07C51/09 , C07C51/41

CPC分类号： C07C51/347 , C07C41/26 , C07C41/44 , C07C45/29 , C07C51/09 , C07C51/412 , C07C205/57 , C07C2603/14 , C07D301/00 , C07D301/32 , C07D303/14 , C07D303/16 , C07D317/22 , C07F7/1804 , C07C59/72 , C07C43/23

摘要： The present invention provides processes for preparing a prostacyclin analog of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.

4.

发明申请
FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS 审中-公开

公开(公告)号：US20150323542A1

公开(公告)日：2015-11-12

申请号：US14801902

申请日：2015-07-17

申请人： Cayman Chemical Company, Incorporated , The Regents of the University of Michigan

发明人： Stephen Douglas Barrett , Daniel Austin Bochar , Levi Lynn Blazer , Fred Lawrence Ciske , Gregory William Endres , Jeffrey Keith Johnson , Gregory Scott Keyes , Ranjinder Singh Sidhu , Raymond C. Trievel , Margaret Lynn Collins

IPC分类号： G01N33/58 , G01N21/64 , C07D519/00 , C07D473/34 , C07D471/04

CPC分类号： G01N33/582 , C07D471/04 , C07D473/34 , C07D519/00 , C07H19/16 , G01N21/6428 , G01N2201/061 , G01N2333/91011

摘要： Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding.

5.

发明申请
METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG 审中-公开

公开(公告)号：US20180141889A1

公开(公告)日：2018-05-24

申请号：US15874093

申请日：2018-01-18

申请人： CAYMAN CHEMICAL COMPANY INCORPORATED

发明人： Kirk William Hering , Gilles Chambournier , Gregory William Endres , Victor Fedij , Thomas James Krell, II , Hussein Mahmoud Mahmoud

IPC分类号： C07C51/347 , C07D301/00 , C07C205/57 , C07C45/29 , C07C41/44 , C07D303/14 , C07D317/22 , C07C51/41 , C07C51/09 , C07C41/26 , C07D301/32 , C07F7/18 , C07D303/16 , C07C59/72 , C07C43/23

摘要： The present invention provides processes for preparing a prostacyclin analogue of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.

6.

发明授权
Methods of synthesizing a prostacyclin analog 有权

公开(公告)号：US10450257B2

公开(公告)日：2019-10-22

申请号：US15874093

申请日：2018-01-18

申请人： CAYMAN CHEMICAL COMPANY INCORPORATED

发明人： Kirk William Hering , Gilles Chambournier , Gregory William Endres , Victor Fedij , Thomas James Krell, II , Hussein Mahmoud Mahmoud

IPC分类号： C07C51/347 , C07D301/32 , C07C41/44 , C07C45/29 , C07D301/00 , C07F7/18 , C07C205/57 , C07C41/26 , C07C51/09 , C07C51/41 , C07D317/22 , C07D303/14 , C07D303/16

摘要： The present invention provides processes for preparing a prostacyclin analog of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.